Literature DB >> 31786448

Long-term use of hypnotics: Analysis of trends and risk factors.

Minori Enomoto1, Shingo Kitamura2, Hisateru Tachimori3, Masahiro Takeshima4, Kazuo Mishima5.   

Abstract

OBJECTIVE: Patients with chronic insomnia are prone to long-term use of hypnotics. Reported risk factors include aging, female sex, and comorbid psychiatric disorders. However, most previous studies have been cross-sectional cohort studies.
METHOD: We conducted a retrospective cohort study using medical service payment data for 330,000 people to determine the duration of prescription of hypnotics and the risk factors for long-term use. We followed up 3981 patients (2382 M, 1599 F, age 40.3 ± 12.4 years) who were prescribed hypnotics for the first time between April 2005 and March 2008.
RESULTS: Of these 3981 patients, 59.6% were prescribed hypnotics for only 1 month, 11.3% were prescribed hypnotics for 2 consecutive months, and 10.1% of patients continued receiving prescriptions for the entire 12-month observation period. In multiple logistic time-dependent Cox analyses, use of antidepressants, mean dose of hypnotics, and advanced age were significantly associated with long-term use of hypnotics (p < 0.01). In an analysis of the association between long-term use of hypnotics and prescribed dosage, high monthly dose, advanced age, and department of first visit were significantly associated with long-term use (p < 0.01).
CONCLUSION: These clinical indicators may be effective for early identification of patients with insomnia who are at high risk of developing physical dependence on hypnotics.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hypnotic; Long-term use; Retrospective cohort study

Mesh:

Substances:

Year:  2019        PMID: 31786448     DOI: 10.1016/j.genhosppsych.2019.11.008

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  7 in total

1.  Efficacy and Safety of Low-Dose Gamma-Aminobutyric Acid From Unpolished Rice Germ as a Health Functional Food for Promoting Sleep: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Seonmin Yoon; Jung-Ick Byun; Won Chul Shin
Journal:  J Clin Neurol       Date:  2022-07       Impact factor: 2.566

Review 2.  Management of Chronic Insomnia Using Cognitive Behavior Therapy for Insomnia (CBT-I) During COVID-19 Pandemic: Does One Shoe Fit All?

Authors:  Arghya Pal; Tanmay Joshi; Aniruddha Basu; Ravi Gupta
Journal:  Sleep Vigil       Date:  2022-03-17

3.  Long-term benzodiazepines and z-drug prescribing in Australian general practice between 2011 and 2018: A national study.

Authors:  Amelia Woods; Mumtaz Begum; David Gonzalez-Chica; Carla Bernardo; Elizabeth Hoon; Nigel Stocks
Journal:  Pharmacol Res Perspect       Date:  2022-02

4.  Sleep pattern and predictors of daily versus as-needed hypnotics use in middle-aged and older adults with insomnia.

Authors:  Maria Tanielian; Jumana Antoun; Munir Sidani; Ahmad Halabi; Malak Hoballah; Kegham Hawatian; Georges Assaf
Journal:  BMC Prim Care       Date:  2022-05-02

5.  Predicting Hypnotic Use among Insomnia Patients with the Theory of Planned Behavior and Craving.

Authors:  Chien-Ming Yang; Yu-Shuan Lai; Yun-Hsin Huang; Ya-Chuan Huang; Hsin-Chien Lee
Journal:  Behav Sci (Basel)       Date:  2022-06-24

6.  Effect of age and sex on prescriptions for outpatients with bipolar disorder in the MUSUBI study: a cross‑sectional study.

Authors:  Yasushi Kawamata; Norio Yasui-Furukori; Naoto Adachi; Hitoshi Ueda; Seiji Hongo; Takaharu Azekawa; Yukihisa Kubota; Eiichi Katsumoto; Koji Edagawa; Eiichiro Goto; Kazuhira Miki; Masaki Kato; Atsuo Nakagawa; Toshiaki Kikuchi; Takashi Tsuboi; Reiji Yoshimura; Kazutaka Shimoda; Koichiro Watanabe
Journal:  Ann Gen Psychiatry       Date:  2022-09-12       Impact factor: 3.301

7.  Different Attitudes of Patients and Psychiatrists Toward Benzodiazepine Treatment.

Authors:  Yasushi Kawamata; Norio Sugawara; Masamichi Ishioka; Kazutoshi Kubo; Katsuji Suzuki; Akira Fujii; Hanako Furukori; Taku Nakagami; Norio Yasui-Furukori; Kazutaka Shimoda
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-15       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.